MDCG on Breakthrough Devices Released
MDCG on Breakthrough Devices Released
Regulatory Affairs Medical Devices In Vitro Diagnostics
Wednesday, 17 December 2025
Kirsten Van Garsse, Authorized Representative Director & Regulatory Affairs Manager IVD
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
On 15 December 2025, the Medical Device Coordination Group (MDCG) published MDCG 2025-9 - Guidance on Breakthrough Devices (BtX) under Regulations 2017/745 & 2017/746, introducing a streamlined regulatory pathway for Breakthrough Devices (BtX) under the MDR and IVDR. The guidance establishes a formal designation process for highly novel devices with a significant positive clinical impact in life-threatening or irreversibly debilitating conditions, enabling accelerated conformity assessment, prioritised engagement with Notified Bodies and Expert Panels, and early market access supported by robust post-market evidence generation.
Play
MDCG on Breakthrough Devices Released | QbD Group Regulatory Update
AI-generated audio
3:57
The guidance sets out the criteria for BtX designation, requiring devices to demonstrate both a high degree of novelty relating to the technology, the associated clinical procedure, or the application of the device in clinical practice, and a reasonably expected significant positive clinical impact on patient or public health. The targeted conditions must be life-threatening, meaning likely to result in death without major medical intervention, or irreversibly debilitating, involving substantial and permanent impairment of daily functioning or quality of life.
MDCG 2025-9 outlines expectations for evidence generation throughout the device lifecycle, including non-clinical and pre-clinical data, as well as pre-market clinical evidence. It explicitly addresses the use of Post-Market Surveillance (PMS) and PMCF/PMPF, noting that, for BtX devices addressing unmet medical needs, placement on the market may be acceptable with more limited pre-market clinical evidence and a higher level of uncertainty, provided that a clear and well-defined plan is in place to collect confirmatory data post-market.
The document further describes the role of Expert Panels, which may provide opinions on BtX designation and offer early scientific advice on clinical development strategies, particularly for high-risk devices. The guidance notes that Expert Panels will endeavour to provide their opinions or advice within 60 days of a request, prioritising devices that have already received a positive BtX status opinion. Applications submitted for BtX status are expected to be prioritised by the Expert Panels.
Finally, the guidance describes procedural supports to facilitate timely market access. Notified Bodies are encouraged to prioritise BtX files during planning, engage in early and structured dialogue with manufacturers, and, where appropriate, issue certificates with specific conditions or provisions, often linked to the completion of PMCF/PMPF activities. MDCG 2025-9 also provides a high-level overview of national and European funding mechanisms supporting innovation, including programmes such as EU4Health and the European Innovation Council (EIC) Accelerator. A pilot to roll out the guidance is expected to be launched in Q2 2026, allowing stakeholders to gain practical experience with the BtX designation process.
What does this mean for you?
For manufacturers of medical devices and IVDs, MDCG 2025-9 introduces a structured pathway for Breakthrough Devices, highlighting opportunities for accelerated conformity assessment and early access to the market for highly innovative products addressing serious or unmet medical needs. Devices that qualify may benefit from prioritised dialogue with Notified Bodies and Expert Panels, potential flexibility on pre-market evidence requirements, and a clear framework for post-market data collection through PMS and PMCF/PMPF. The guidance also signals upcoming procedural pilots and support mechanisms, helping manufacturers plan ahead for regulatory interactions and early certification.
Get in touch with our experts
Should you want to discuss this more in-depth with one of our consultants, please do not hesitate to contact us.
Discover more expert content
Previous
Regulatory Affairs
14 May 2025
New Manufacturer Incident Report template and IMDRF terminologies for categorized Adverse Event Reporting released
This template will become mandatory as from November 2025. Next to the pdf template, also the MIR ...
Regulatory Affairs
9 Jul 2024
MDCG: First Revision on the Guidance on Standardisation for Medical Devices
MDCG 2021-05 Revision 1: Guidance on standardization for medical devices The scope of this...
Regulatory Affairs
24 Dec 2024
MDCG 2022-3 Rev.1 released
Notified bodies are required to verify product batches of class D IVDs. Therefore, manufacturers...
Regulatory Affairs
27 Jan 2025
New revisions of the Preliminary Assessment Review templates, forms and annexes
The documents are available in the Notified Body section of the MDCG Guidance webpage. The...
Regulatory Affairs
27 Jan 2025
Second revision to MDCG 2023-3 Guidance document released
MDCG 2023-3 Rev. 2: Questions and Answers on vigilance terms and concepts as outlined in the...
Regulatory Affairs
14 May 2025
New Manufacturer Incident Report template and IMDRF terminologies for categorized Adverse Event Reporting released
This template will become mandatory as from November 2025. Next to the pdf template, also the MIR ...
Regulatory Affairs
9 Jul 2024
MDCG: First Revision on the Guidance on Standardisation for Medical Devices
MDCG 2021-05 Revision 1: Guidance on standardization for medical devices The scope of this...
Regulatory Affairs
24 Dec 2024
MDCG 2022-3 Rev.1 released
Notified bodies are required to verify product batches of class D IVDs. Therefore, manufacturers...
Regulatory Affairs
27 Jan 2025
New revisions of the Preliminary Assessment Review templates, forms and annexes
The documents are available in the Notified Body section of the MDCG Guidance webpage. The...
Regulatory Affairs
27 Jan 2025
Second revision to MDCG 2023-3 Guidance document released
MDCG 2023-3 Rev. 2: Questions and Answers on vigilance terms and concepts as outlined in the...
Regulatory Affairs
14 May 2025
New Manufacturer Incident Report template and IMDRF terminologies for categorized Adverse Event Reporting released
This template will become mandatory as from November 2025. Next to the pdf template, also the MIR ...
Regulatory Affairs
9 Jul 2024
MDCG: First Revision on the Guidance on Standardisation for Medical Devices
MDCG 2021-05 Revision 1: Guidance on standardization for medical devices The scope of this...
Next
- 1
- 2
- 3
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Twitter Widget Iframe